South San Francisco, CA October 11, 2023 Press Release Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based…
Tag: Ocrelizumab
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis
South San Francisco, CA October 26, 2017 Genentech Press Release New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression…